Utilizing buprenorphine-naloxone to treat illicit and prescription-opioid dependence

Neuropsychiatric Disease and Treatment

Volumn 10, Issue , 2014, Pages 587-598

  Mauger, Sofie ^a   Fraser, Ronald ^a,b   Gill, Kathryn ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Clinical management; Methadone; Opiate detoxification; Opiate substitution; Suboxone; Zubsolv

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BUPRENORPHINE PLUS NALOXONE; DIAMORPHINE; ILLICIT DRUG; METHADONE; MORPHINE; OPIATE; OXYCODONE; PLACEBO;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONSTIPATION; DIAPHORESIS; DIARRHEA; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEPENDENCE; DRUG DEPENDENCE TREATMENT; DRUG DETOXIFICATION; DRUG DISTRIBUTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; FATIGUE; FIRST PASS EFFECT; HEADACHE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; MYDRIASIS; NAUSEA; OPIATE ADDICTION; OUTCOME ASSESSMENT; PAIN; PATIENT CARE; PATIENT MONITORING; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFLEX; RESPIRATION DEPRESSION; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK FACTOR; RISK REDUCTION; SIDE EFFECT; SWEATING; SYSTEMATIC REVIEW; VIRUS TRANSMISSION; VOMITING; WITHDRAWAL SYNDROME; YAWNING;

EID: 84898715479     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S39692     Document Type: Article

References (118)

1. Degenhardt L, Bucello C, Calabria B, et al. What data are available on the extent of illicit drug use and dependence globally? Results of four systematic reviews. Drug Alcohol Depend. 2011;117:85-101.
2. Fischer B, Argento E. Prescription opioid related misuse, harms, diversion and interventions in Canada: a review. Pain Physician. 2012;5:ES191-ES203.
3. Friedland G. Infectious disease comorbidities adversely affecting substance users with HIV: hepatitis C and tuberculosis. J Acquir Immune Defic Syndr. 2010;55:S37-S42.
4. Stockman JK, Strathdee SA. HIV among people who use drugs: a global perspective of populations at risk. J Acquir Immune Defic Syndr. 2010;55:S17-S22.
5. Substance Abuse and Mental Health Services Administration (SAMHSA). State Estimates of Substance Use and Mental Disorders from the 2008-2009 National Surveys on Drug Use and Health. Rockville, MD: SAMHSA; 2011.
6. United Nations Office on Drugs and Crime (UNODC). World Drug Report 2013. Vienna: UN; 2013. Available from: http://www.unodc.org/unodc/secured/wdr/wdr2013/World_Drug_Report_2013.pdf. Accessed November 18, 2013.
7. European Monitoring Center on Drugs and Drug Abuse (EMCDDA). Annual Report 2011: The State of the Drugs Problem in Europe. Luxembourg: EMCDDA; 2011. Available from: http://www.emcdda.europa.eu/publications/annual-report/2011. Accessed November 18, 2013.
8. Holmes D. Prescription drug addiction: the treatment challenge. Lancet. 2012;379:17-18.
9. Royal Australasian College of Physicians (RACP). Prescription Opioid Policy: Improving Management of Chronic Nonmalignant Pain and Prevention of Problems Associated with Prescription Opioid Use. Sydney: RACP; 2009. Available from: https://www.racp.edu.au/index.cfm?objectid=EA87198D-CA47-AB21-072D9B2F26FD4AA3. Accessed November 18, 2013.
10. Sigmon S. Characterizing the emerging population of prescription opioid abusers. Am J Addict. 2006;15:208-212.
11. Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network, 2011: national estimates of drug-related emergency department visits. 2013. Available from: http://www.Samhsa.gov/data/2k13/DAWN2k11ED/DAWN2k11ED.htm. Accessed November 18, 2013.
12. Gwin Mitchell S, Kelly SM, Brown BS, et al. Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland. Am J Addict. 2009;18:346-355.
13. Sohler NL, Li X, Kunins HV, et al. Home- versus office-based buprenorphine induction for opioid-dependent patients. J Subst Abuse Treat. 2010;38:153-159.
14. Amato L, Minozzi S, Davoli M, Vecchi S. Psychosocial and pharmacological treatments versus pharmacological treatments for opioid detoxification. Cochrane Database Syst Rev. 2011 9: CD005031.
15. Friedman SR, Tempalski B, Cooper H, et al. Estimating numbers of injecting drug users in metropolitan areas for structural analyses of community vulnerability and for assessing relative degrees of service provision for injecting drug users. J Urban Health. 2004;81: 377-400.
16. Peterson JA, Schwartz RP, Mitchell SG, et al. Why don't out-of-treatment individuals enter methadone treatment programs? Int J Drug Policy. 2010;21:36-42.
17. Popova S, Rehm J, Fischer B. An overview of illegal opioid use and health services utilization in Canada. Public Health. 2006;120:320-328.
18. Auriacombe M, Fatseas M, Dubernet J, Daulouede JP, Tignol J. French field experience with buprenorphine. Am J Addict. 2004;13:S17-S28.
19. Fatseas M, Auriacombe M. Why buprenorphine is so successful in treating opiate addiction in France. Curr Psychiatry Rep. 2007;9:358-364.
20. Moore B, Fiellin DA, Barry DT, et al. Primary care office-based buprenorphine treatment: comparison of heroin and prescription opioid dependent patients. J Gen Intern Med. 2007;22:527-530.
21. Fiellin DA. The first three years of buprenorphine in the United States: experience to date and future directions. J Addict Med. 2007;1: 62-67.
22. Knudsen HJ, Abraham AJ, Johnson JA, Roman PM. Buprenorphine adoption in the National Drug Abuse Treatment Clinical Trials Network. J Subst Abuse Treat. 2009;37:307-312.
23. Parran TV, Adelman CA, Merkin B, et al. Long-term outcomes of office-based buprenorphine/naloxone maintenance therapy. Drug Alcohol Depend. 2010;106:56-60.
24. Bell J, Trinh L, Butler B, Randall D, Rubin G. Comparing retention in treatment and mortality in people after initial entry to methadone and buprenorphine treatment. Addiction. 2009;104:1193-1200.
25. Jones ES, Moore BA, Sindelar JL, O'Connor PG, Schottenfeld RS, Fiellin DA. Cost analysis of clinic and office-based treatment of opioid dependence: results with methadone and buprenorphine in clinically stable patients. Drug Alcohol Depend. 2009;99:132-140.
26. Nielsen S, Dietze P, Cantwell K, Lee N, Taylor D. Methadone and buprenorphine related ambulance attendances: a population-based indicator of adverse events. J Subst Abuse Treat. 2008;35: 457-461.
27. Smith MY, Bailey JE, Woody GE, Kleber HD. Abuse of buprenorphine in the United States: 2003-2005. Journal of Addictive Diseases 2007;26:107-111.
28. Virani AS, Bezchlibnyk-Butler KZ, Jeffries JJ, Procyshyn RM. Clinical Handbook of Psychotropic Drugs. 19th ed. Bern: Hogrefe and Huber; 2012.
29. Mello NK, Mendelson J. Behavioral pharmacology of buprenorphine. Drug Alcohol Depend. 1985;14:283-303.
30. Lutfy K, Cowan A. Buprenorphine: a unique drug with complex pharmacology. Curr Neuropharmacol. 2004;2:395-402.
31. Walsh S, Preston K, Stitzer M, Cone E, Bigelow G. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994;55:569-580.
32. Strain EC, Preston K, Liebson I, Bigelow G. Buprenorphine effects in methadone-maintained volunteers: effect at two hours after methadone. J Pharmacol Exp Ther. 1995;272:628-638.
33. Centre for Addiction and Mental Health. Buprenorphine/Naloxone for Opioid Dependence: Clinical Practice Guideline. Toronto: CAMH; 2012. Available from: http://knowledgex.camh.net/primary_care/guidelines_materials/Documents/buprenorphine_naloxone_gdlns2012.pdf. Accessed November 18, 2013.
34. Substance Abuse and Mental Health Services Administration. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction: A Treatment Improvement Protocol (TIP) 40. Rockville, MD: SAMHSA; 2004. Available from: http://buprenorphine.samhsa.gov/Bup_Guidelines.pdf. Accessed November 18, 2013.
35. Wesson DR. Buprenorphine in the treatment of opiate dependence: its pharmacology and social context of use in the US. J Psychoactive Drugs. 2004;Suppl 2:119-128.
36. Amass L, Ling W, Freese TE, et al. Bringing buprenorphine-naloxone detoxification to community treatment providers: the NIDA clinical trials network field experience. Am J Addict. 2004;13 Suppl 1: S42-S66.
37. Caldiero R, Parran T, Adelman C, Piche B. Inpatient initiation of buprenorphine maintenance vs detoxification: can retention of opioid-dependent patients in outpatient counseling be improved? Am J Addict. 2006;15:1-7.
38. White J, Bell J, Saunders J, et al. Open-label dose-finding trial of buprenorphine implants (Probuphine) for treatment of heroin dependence. Drug Alcohol Depend. 2009;103:37-43.
39. Schuh K, Walsh S, Stitzer M. Onset, magnitude and duration of opioid blockade produced by buprenorphine and naltrexone in humans. Psychopharmacology. 1999;145:162-174.
40. Ling W, Jacobs P, Hillhouse M, et al. From research to the real world: buprenorphine in the decade of the Clinical Trials Network. J Subst Abuse Treat. 2010;38 Suppl 1:S53-S60.
41. Chiang CN, Hawks RL. Pharmacokinetics of the combination tablet of buprenorphine and naloxone. Drug Alcohol Depend. 2003; 70 Suppl 2:S39-S47.
42. Bigelow GE, Preston K, Liebson I. Abuse liability assessment of buprenorphine-naloxone combinations. NIDA Res Monogr. 1987;76: 145-149.
43. Preston KL, Bigelow G, Liebson I. Buprenorphine and naloxone alone and in combination in opioid-dependent humans. Psychopharmacology. 1988;94:484-490.
44. US Food and Drug Administration, Drugs@FDA: FDA-approved drug products. Available from: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm. Accessed November 18, 2013.
45. Community Care Behavioral Health Organization. Supporting recovery from opioid addiction: community care best practice guidelines for buprenorphine and Suboxone. 2013. Available from: http://www.ct.gov/dmhas/lib/dmhas/publications/Community_Care_BP_Guidelines_for_Buprenorphine_and_Suboxone.pdf. Accessed November 18, 2013.
46. Broers B, Giner F, Dumont P, Mino A. Inpatient opiate detoxification in Geneva: follow-up at 1 and 6 months. Drug Alcohol Depend. 2000;58:85-92.
47. Gossop M. Clonidine and the treatment of the opiate withdrawal syndrome. Drug Alcohol Depend. 1988;21:253-259.
48. Vaillant GE. What can long-term follow-up teach us about relapse and prevention of relapse in addiction? Br J Addict. 1988;83:1147-1157.
49. Cornish R, Macleod J, Strang J, Vickerman P, Hickman M. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ. 2010;341:c5475.
50. Kimber J, Copeland L, Hickman M, et al. Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. BMJ. 2010;341:c3172.
51. Dole VP, Nyswander ME. Heroin addiction - a metabolic disease. Arch Intern Med. 1967;120:19-24.
52. Johnson RE, Strain EC, Amass L. Buprenorphine: how to use it right. Drug Alcohol Depend. 2003;70:S59-S77.
53. Fiellin D, Kleber H, Trumble-Hejduk J, McLellan A, Kosten T. Consensus statement on office-based treatment of opioid dependence using buprenorphine. J Subst Abuse Treat. 2004;27:153-159.
54. Schering-Plough Canada. Suboxone Product Monograph. Kirkland, QC: Schering-Plough Canada; 2007.
55. Kosten TR, O'Connor PG. Management of drug and alcohol withdrawal. N Engl J Med. 2003;348:1786-1795.
56. Dijkstra BA, Krabbe PF, De Jong CA, van der Staak CP. Prediction of withdrawal symptoms during opioid detoxification. J Opioid Manag. 2008;4:311-319.
57. Farrell M. Opiate withdrawal. Addiction. 1994;89:1471-1475.
58. Kleber H. Detoxification from narcotics. In: Lowinson JH, Ruiz P, editors. Substance Abuse. Baltimore: Williams & Wilkins; 1981.
59. Tompkins DA, Bigelow GE, Harrison JA, Johnson RE, Fudala PJ, Strain EC. Concurrent validation of the Clinical Opiate Withdrawal Scale (COWS) and single-item indices against the Clinical Institute Narcotic Assessment (CINA) opioid withdrawal instruments. Drug Alcohol Depend. 2009;105:154-159.
60. Gunderson EW, Levin FR, Rombone MM, Vosburg SK, Kleber HD. Improving temporal efficiency of outpatient buprenorphine induction. Am J Addict. 2011;20:397-404.
61. Ducharme S, Fraser R, Gill K. Update on the clinical use of buprenorphine in opioid-related disorders. Can Family Physician. 2012;58:37-41.
62. Mattick R, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008;2:CD002207.
63. Nielsen S, Hillhouse M, Thomas C, Hasson A, Ling W. A comparison of buprenorphine taper outcomes between prescription opioid and heroin users. J Addict Med. 2013;7:33-38.
64. Soyka M, Zingg C, Koller G, Kuefner H. Retention rate and substance use in methadone and buprenorphine maintenance therapy and predictors of outcome: results from a randomized study. Int J Neuropsychopharmacol. 2008;11:641-653.
65. Whitley SD, Sohler NL, Kunins HV, et al. Factors associated with complicated buprenorphine inductions. J Subst Abuse Treat. 2010;39:51-57.
66. Doran CM. Buprenorphine, buprenorphine/naloxone and methadone maintenance: a cost-effectiveness analysis. Expert Rev Pharmacoecon Outcomes Res. 2005;5:583-591.
67. Bonhomme J, Shim RS, Gooden R, Tyus D, Rust G. Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options. J Natl Med Assoc. 2012;104:342-350.
68. Lee JD, Grossman E, DiRocco D, Gourevitch MN. Home buprenorphine/naloxone induction in primary care. J Gen Intern Med. 2009;24: 226-232.
69. Walley AY, Alperen JK, Cheng DM, et al. Office-based management of opioid dependence with buprenorphine: clinical practices and barriers. J Gen Intern Med. 2008;23(9):1393-1398.
70. Mintzer IL, Eisenberg M, Terra M, MacVane C, Himmelstein DU, Woolhandler S. Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings. Ann Fam Med. 2007;5(2):146-150.
71. Gunderson EW, Wang XQ, Fiellin DA, Bryan B, Levin FR. Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial. Addict Behav. 2010;35:537-540.
72. Farrell M, Wodak A, Gowing L. Maintenance drugs to treat opioid dependence. BMJ. 2012;344:e2823.
73. Kraus ML, Alford DP, Kotz MM, et al. Statement of the American Society of Addiction Medicine Consensus Panel on the use of buprenorphine in office-based treatment of opioid addiction. J Addict Med. 2011;5:254-263.
74. Ehret GB, Desmeules JA, Broers B. Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology. Expert Opin Drug Saf. 2007;6:289-303.
75. Fishman MJ, Wu LT, Woody GE. Buprenorphine for prescription opioid addiction in a patient with depression and alcohol dependence. Am J Psychiatry. 2011;168:675-679.
76. Martell BA, Arnsten JH, Krantz MJ, Gourevitch MN. Impact of methadone treatment on cardiac repolarization and conduction in opioid users. Am J Cardiol. 2005;95:915-918.
77. Whitley SD, Kunins HV, Arnsten JH, Gourevitch MN. Colocating buprenorphine with methadone maintenance and outpatient chemical dependency services. J Subst Abuse Treat. 2007;33:85-90.
78. Manelli P, Peindl KS, Lee T, Bhatia KS, Wu LT. Buprenorphine-mediated transition from opioid agonist to antagonist treatment: state of the art and new perspectives. Curr Drug Abuse Rev. 2012;5: 52-63.
79. Knudsen HK, Ducharme LJ, Roman PM. Early adoption of buprenorphine in substance abuse treatment centers: data from the private and public sectors. J Subst Abuse Treat. 2006;30:363-373.
80. Baxter LE. Clinical Guidance on Methadone Induction and Stabilization. Chevy Chase (MD): American Society of Addiction Medicine; 2009.
81. Joseph H, Stancliff S, Lagrod J. Methadone maintenance treatment (MMT): a review of historical and clinical issues [review]. Mt Sinai J Med. 2000;67:347-364.
82. Ling W, Charuvastra C, Collins J, et al. Buprenorphine maintenance treatment of opiate dependence: a multicenter randomized clinical trial. Addiction. 1998;93:475-486.
83. Ahmadi J. Methadone versus buprenorphine maintenance for the treatment of heroin-dependent outpatients. J Subst Abuse Treat. 2003;24:217-220.
84. Kakko J, Grönbladh L, Svanborg K, et al. A stepped care strategy using buprenorphine and methadone versus conventional methadone maintenance in heroin dependence: a randomized controlled trial. Am J Psychiatry. 2007;164:797-803.
85. Fareed A, Vayalapalli S, Casarella J, Dexler K. Treatment outcome for flexible dosing buprenorphine maintenance treatment. Am J Drug Alcohol Abuse. 2012;38:155-160.
86. World Health Organization. Guidelines for the Psychosocially Assisted Pharmalogical Treatment of Opioid Dependence. Geneva: WHO; 2009. Available from: http://www.who.int/substance_abuse/publications/opioid_dependence_guidelines.pdf. Accessed January 30, 2014.
87. Wang R, Young L. Double-blind controlled detoxification from buprenorphine. NIDA Res Monogr. 1996;162:114.
88. Pycha C, Resnick R, Galanter M. Buprenorphine: rapid and slow dose-reduction for heroin detoxification. NIDA Res Monogr. 1994;141:453.
89. Amass L, Bickel W, Higgins S, Hughes J. A preliminary investigation of outcome following gradual or rapid buprenorphine detoxification. J Addict Dis. 1994;13:33-45.
90. Ling W, Hillhouse M, Dornier C, et al. Buprenorphine tapering schedule and illicit opioid use. Addiction. 2009;104:256-265.
91. Katz EC, Schwartz RP, King S, et al. Brief vs extended buprenorphine detoxification in a community treatment program: engagement and short term outcomes. Am J Drug Alcohol Abuse. 2009;35:63-67.
92. Kleber HD, Weiss RD, Anton RF, et al. Practice guidelines for the treatment of patients with substance use disorders, second edition. Arlington (VA): American Psychiatric Association (APA); August 2006. http://psychiatryonline.org/pdfaccess.ashx?ResourceID=243188&PDFSource=6. Accessed November 18, 2013.
93. Dutra L, Stathopoulou G, Basden SL, Leyro TM, Powers MB, Otto MW. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry. 2008;165:179-187.
94. Pendergast M, Podus D, Finney J, Greenwell L, Roll J. Contingency management for treatment of substance use disorders: a meta-analysis. Addiction. 2010;101:1546-1560.
95. Campbell BK, Fuller BE, Lee ES. Facilitating outpatient treatment entry following detoxification. Psychology of Addictive Behaviours. 2009;23(2):260-270.
96. Fiellin DA, Pantalon M, Chawarski M, et al. Counselling plus buprenorphine-naloxone maintenance therapy for opioid dependence. N Engl J Med. 2006;355:365-374.
97. Weiss RD, Potter JS, Provost SE, et al. A multi-site, two-phase, Prescription Opioid Addiction Treatment Study (POATS): Rationale, design, and methodology. Contemp Clin Trials. 2010;31:189-199.
98. Wedam EF, Bigelow G, Johnson R, Nuzzo P, Haigney M. QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial. Arch Intern Med. 2007;167:2469-2475.
99. Ancherson K, Clausen T, Gossop M, Hansteen V, Waal H. Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study. Addiction. 2009;104:993-999.
100. Lange WR, Fudala P, Dax E, Johnson R. Safety and side-effects of buprenorphine in the clinical management of heroin addiction. Drug Alcohol Depend. 1990;26:19-28.
101. Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349:949-958.
102. Orman JS, Keating GM. Buprenorphine/naloxone: a review of its use in the treatment of opioid dependence. Drugs. 2009;69:577-607.
103. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement for opioid dependence. Cochrane Database Syst Rev. 2009;3:CD002209.
104. Fischer G, Ortner R, Rohrmeister K, et al. Methadone versus buprenorphine in pregnant addicts: a double-blind, double-dummy comparison study. Addiction. 2006;101:275-281.
105. Lavie E, Fatseas M, Denis C, Auriacombe M. Benzodiazepine use among opiate-dependent subjects in buprenorphine maintenance treatment: correlates of use, abuse and dependence. Drug Alcohol Depend. 2009;99:338-344.
106. House of Delegates of the Federation of State Medical Boards. Model Policy on DATA 2000 and Treatment of Opioid Addiction in Medical Offices. United States: Federation of State Medical Boards; April 2013. Available from: http://www.fsmb.org/pdf/2013_model_policy_treatment_opioid_addiction.pdf. Accessed January 2014.
107. Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy: effects and management. Obstet Gynecol Clin North Am. 1998;25:139-151.
108. Fajemirokun-Odudeyi O, Sinha C, Tutty S, et al. Pregnancy outcome in women who use opiates. Eur J Obstet Gynecol Reprod Biol. 2006;126:170-175.
109. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363:2320-2331.
110. Jones HE, Fischer G, Heil SH, et al. Maternal Opioid Treatment: Human Experimental Research (MOTHER) - approach, issues, and lessons learned. Addiction. 2012;107 Suppl 1:28-35.
111. Academy of Breastfeeding Medicine Protocol Committee, Jansson LM. ABM Clinical Protocol #21: Guidelines for Breastfeeding and the Drug-Dependent Woman. Breastfeed Med. 2009;4:225-228.
112. Hayes BD, Klein-Schwartz W, Doyon S. Toxicity of buprenorphine overdoses in children. Pediatrics. 2008;121:e782-e786.
113. Bell J, Mutch C. Treatment retention in adolescent patients treated with methadone or buprenorphine for opioid dependence: a file review. Drug Alcohol Rev. 2006;25:167-171.
114. Woody G, Poole SA, Subramaniam G, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA. 2008;300:2003-2011.
115. Fiellin DA. Treatment of adolescent opioid dependence: no quick fix. JAMA. 2008;300:2057-2059.
116. Levy S, Vaughan BL, Angulo M, Knight JR. Buprenorphine replacement therapy for adolescents with opioid dependence: early experience from a children's hospital-based outpatient treatment program. J Adolesc Health. 2007;40:477-488.
117. Altice FL, Bruce RD, Lucas GM, et al. HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr. 2011;56 Suppl 1: S22-S32.
118. McCance-Katz EF, Sullivan LS, Nallani S. Drug interactions of clinical importance between the opioids, methadone and buprenorphine, and frequently prescribed medications: a review. Am J Addict. 2009;19:4-16.